Winona Pricing Analysis & Total Cost: What You Actually Pay for Telehealth HRT in 2026

Winona is a direct-to-consumer telehealth platform that connects menopausal patients with licensed clinicians who prescribe compounded bioidentical hormones (typically estradiol, progesterone, DHEA, and sometimes testosterone) shipped from partner compounding pharmacies. It is not itself a drug, a manufacturer, or an FDA-approved product line. This distinction matters for cost, because the price you pay is driven less by the hormone itself and more by whether the formulation is compounded to order or dispensed as a commercially manufactured, FDA-approved generic.

The pricing question that actually matters is not "is Winona expensive" but "am I paying a compounding premium for a formulation that has an FDA-approved, insurance-eligible equivalent." Publicly advertised subscription prices for Winona have been reported in the roughly $89 to $199 per month range as of this writing (2026); readers should confirm current pricing on Winona's own site, since telehealth pricing changes without notice. By comparison, FDA-approved generic estradiol patches and oral micronized progesterone commonly cost $15 to $45 per month at retail pharmacies when a discount card or insurance applies. For a patient whose clinical picture does not require a custom formulation, the difference is largely a convenience and access premium, not a difference in the active ingredient.

How Winona's pricing model works

Winona uses a subscription structure in which the provider consultation is bundled into the recurring medication charge rather than billed as a separate office visit. Patients complete an online intake, a clinician reviews it (the degree of live, synchronous interaction can vary by visit type), and a prescription is shipped from a compounding pharmacy.

Because Winona does not bill insurance, the full subscription price is out-of-pocket. This is a real trade-off: no insurance paperwork, but no insurance discount either. Patients comparing costs should separate two things that are often bundled together in marketing: the price of accessing a clinician, and the price of the specific formulation prescribed.

An important regulatory fact anchors this whole comparison. The FDA has stated that compounded drugs "are not FDA-approved" and "do not undergo FDA premarket review for safety, effectiveness, or quality" (FDA, Compounding and the FDA: Questions and Answers). That does not mean compounded hormones are unsafe, and compounding serves a legitimate purpose when no commercially available product meets a patient's specific clinical need. But when an FDA-approved equivalent already exists at the same dose and route, the compounded version is priced independently of that regulatory pathway, and the price difference reflects that.

What does Winona prescribe, and is it interchangeable with FDA-approved products?

Winona's formulary is described publicly as centering on topical estradiol, oral micronized progesterone, vaginal DHEA, and in some cases compounded testosterone cream for postmenopausal women. Testosterone is not FDA-approved for use in women in the United States; when it is prescribed for symptoms such as low libido, that is an off-label use, not an FDA-approved indication.

For estradiol and progesterone specifically, FDA-approved generic versions exist and are widely stocked at retail pharmacies. The North American Menopause Society's guidance states that FDA-approved hormone therapy is preferred as first-line treatment when an equivalent product is available, and that custom-compounded bioidentical preparations carry the same general safety considerations as FDA-approved products plus an additional concern about batch-to-batch consistency, since compounded products are not subject to the same manufacturing quality controls (see NAMS / menopause.org). This is a guideline-level statement from an accountable professional society, not a claim that compounded hormones are dangerous.

A separate, practical access problem shapes why patients turn to platforms like Winona at all: many general OB-GYN and primary care training programs provide limited formal menopause-specific education, a gap that has been discussed in the menopause literature and by clinical societies, though exact survey percentages vary by study and should be checked against the specific paper before being cited as a fixed figure. That access gap is real and helps explain the appeal of an all-in-one telehealth subscription, separate from whether the pricing is competitive.

Is Winona legit?

Winona operates as a licensed telehealth company using licensed physicians or nurse practitioners prescribing within state scope-of-practice rules. Nothing in the public record reviewed for this article indicates it is fraudulent. The more useful question for a prospective patient is not legitimacy but clinical fit: does the intake and prescribing process gather enough information to individualize hormone therapy the way major guidelines recommend.

The Endocrine Society's clinical practice guideline on menopausal hormone therapy calls for individualized treatment based on symptom severity, time since menopause onset, and cardiovascular risk. Timing matters: hormone therapy's risk-benefit balance differs for women who start therapy close to menopause onset versus many years later, a finding that traces back to subgroup analyses of the Women's Health Initiative (WHI), the large randomized trial of postmenopausal hormone therapy conducted in the late 1990s and early 2000s. The exact hazard ratios reported in WHI publications and later reanalyses vary by outcome and by which WHI arm is being discussed, so specific numbers should be checked against the original WHI publications rather than repeated from memory.

Asynchronous, form-based telehealth intake models have been scrutinized in the broader telehealth prescribing literature for potentially limiting real-time, shared decision-making compared with live visits. Winona reportedly offers messaging and follow-up visits with providers, so it is not purely asynchronous, but patients should still expect to actively raise their own risk factors (personal or family history of breast cancer, blood clots, cardiovascular disease) rather than assume the intake form alone will surface them.

Winona versus alternatives: what pricing structures look like

Telehealth HRT platforms use meaningfully different pricing models, and the model matters more than the sticker price alone.

• Midi Health has been publicly described as charging a per-visit consultation fee with lower-cost follow-ups, and prescribing FDA-approved hormones fillable at retail pharmacies, which allows insurance to apply to the medication cost.
• Evernow has been publicly described as using a monthly subscription model, similar in structure to Winona, generally covering compounded formulations.
• Alloy Health has been publicly described as charging separate consultation and follow-up fees, with medications billed through retail pharmacies rather than bundled compounding.
• Traditional in-office care with an OB-GYN or endocrinologist typically involves either an insurance copay or a self-pay office visit fee, with medications priced at standard pharmacy rates when FDA-approved generics are used.

Exact current dollar figures for competitor platforms change frequently and were not independently verified against each company's live pricing page for this article; readers comparing options should check each platform's current published pricing directly rather than relying on cached figures. The structural pattern that does hold up: subscription-model compounding platforms (Winona, Evernow) tend to bundle consultation and compounded medication into one recurring charge, while per-visit models paired with retail-pharmacy prescribing (Midi, Alloy, traditional in-office care) let insurance and discount cards reduce the medication portion of the bill, often at the cost of paying separately for visits.

The compounding premium, in plain terms

A meaningful part of what a patient pays through a compounding-based subscription reflects the compounding process itself: custom mixing, non-standard doses or delivery forms, and a supply chain outside standard pharmaceutical distribution. FDA guidance generally recognizes that compounding fills a legitimate need when a patient requires a formulation, dose, or dosage form that is not commercially available. When that specific clinical need exists, the premium may be justified. When an FDA-approved equivalent at an equivalent dose is available, the compounded version does not have demonstrated superior efficacy, and some published comparisons of compounded versus FDA-approved transdermal estradiol have reported greater variability in achieved serum hormone levels with compounded preparations, though the specific study and its exact findings should be verified against the primary publication before being cited as settled evidence.

Hidden costs and what a subscription typically does not include

Most telehealth HRT subscriptions, Winona included, are priced around consultation and medication only. Several things commonly sit outside that price:

Lab work. Baseline and follow-up labs (lipid panels, liver function, and sometimes serum hormone levels) are standard parts of HRT monitoring per Endocrine Society guidance, but are typically ordered and billed separately from the subscription.

Mammography and breast cancer screening. The U.S. Preventive Services Task Force recommends breast cancer screening for average-risk women in the relevant age range regardless of HRT status; this does not change because a patient is on hormone therapy (see USPSTF breast cancer screening recommendation). Combined estrogen-progestogen therapy has been associated with a small increase in breast cancer incidence in WHI data; the exact magnitude should be checked against the primary WHI publications rather than a secondhand figure.

Bone density screening. Estrogen therapy has documented bone-protective effects in trial data, which is one reason some patients start it; a baseline DEXA scan is a reasonable conversation to have with a prescriber but is not something a subscription-only telehealth model typically arranges.

Factoring in external labs and preventive screening adds a real, if variable, amount to the true annual cost of any HRT regimen, cash-pay or insured.

Evidence boundary: what is established, what is not

Established: Compounded drugs, including Winona's hormone formulations, are not FDA-approved and do not go through FDA premarket review. FDA-approved generic estradiol and progesterone exist and are eligible for insurance and discount-card pricing at retail pharmacies. Guideline bodies (NAMS, Endocrine Society) state a general preference for FDA-approved hormone therapy when an equivalent formulation exists. Testosterone is not FDA-approved for women in the United States; its use for postmenopausal symptoms is off-label.

Plausible but not rigorously confirmed here: That compounded transdermal estradiol produces more variable serum levels than FDA-approved patches has been reported in at least some published comparisons, but the specific study, its sample size, and its confidence intervals require direct verification before being treated as a settled number.

Not established from the material reviewed for this article: Precise, current dollar comparisons between Winona and named competitor platforms (Midi Health, Evernow, Alloy Health), because public pricing for cash-pay telehealth companies changes without notice and was not independently re-verified live for this draft. Exact percentages for how many OB-GYN residencies teach menopause management, exact WHI hazard ratios by outcome, and any specific named-individual quote about compounded bioidentical hormones should all be checked against primary sources before being repeated as fixed facts in a published version of this page.

How to evaluate whether you are overpaying

Check your insurance formulary first. Generic estradiol and oral micronized progesterone are on most formularies at low tiers. If your copay is in the $10 to $30 range, a subscription priced well above that for the same active ingredients is buying convenience, not a different drug.

Price-check a retail pharmacy or discount card before enrolling anywhere. Compare the all-in subscription price against what the same active ingredient costs filled locally.

Ask why a compounded formulation was chosen over an FDA-approved one. A legitimate reason exists when a dose, combination, or delivery form is not commercially manufactured, or when a patient has a documented allergy to an inactive ingredient in the approved product. If no such reason applies, ask the prescriber directly.

Add in labs and screening before comparing total cost. A subscription price that looks lower than in-office care can look different once labs, mammography, and any DEXA scan are added back in.

Weigh access honestly. In areas with few practicing OB-GYNs or menopause-trained clinicians, a documented and ongoing workforce shortage in some regions, a telehealth premium may be a reasonable trade for actually getting seen. ACOG's own workforce reporting has flagged geographic disparities in OB-GYN availability (see ACOG workforce report).

Public claims versus verifiable evidence